VISX sees US rivals set to mount licence challenge
This article was originally published in Clinica
Executive Summary
VISX failed just before Christmas to protect three of its laser optical surgery patents in Canada, fuelling speculation that rivals such as Nidek, Bausch & Lomb and LaserSight may now be able to break the dominant position VISX claims in the US, the only country where it demands per-use licence fees of $250.